M2 Pharma - Policy and Regulations

Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy

14 May 2021 - - US-based biopharma company Osmol Therapeutics has initiated Investigational New Drug enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy, the co...

Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

14 May 2021 - - US-based precision medicine company Gemini Therapeutics, Inc. (NASDAQ: GMTX) has completed enrollment in its Phase 2a trial advancing GEM103 as a potential add-on therapy for patients ...

India Globalization Capital Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients

14 May 2021 - - US-based cannabinoid-based therapies developer India Globalization Capital, Inc. (NYSE American: IGC) it has completed Cohort 1 of its Phase 1 clinical trial testing IGC's tetrahy...

Hannah Named to Rigel Pharmaceuticals Board of Directors

14 May 2021 - - US-based biotechnology company Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) has appointed Alison L. Hannah, M.D. to its board of directors, the company said.

Rigel...

Antengene receives China regulatory approval for eltanexor Phase Ib/II open-label, multicentre, dose-escalation study

14 May 2021 - Antengene Corporation Limited (SEHK: 6996.HK), a China-based biopharmaceutical company, has received approval from China's National Medical Products Administration (NMPA) for the st...

Astellas Pharma receives Japanese regulator priority review approval for enfortumab vedotin New Drug Application

14 May 2021 - Japan-based Astellas Pharma Inc (TSE: 4503) announced on Thursday that Japan's Ministry of Health, Labour and Welfare has given priority review for the firm's New Drug Applicat...